表紙
市場調查報告書

肝炎病毒迅速、POC (照護現場) 檢驗:醫療設備的開發平台評估

Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 550307
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
Back to Top
肝炎病毒迅速、POC (照護現場) 檢驗:醫療設備的開發平台評估 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年11月14日內容資訊: 英文 130 Pages
簡介

本報告提供全球肝炎病毒的迅速檢驗及POC (照護現場) 檢驗的市場上的主要開發中產品 (醫療設備) 的臨床實驗的進展調查,產品特性比較分析 (臨床實驗的各進展階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易、產業聯盟等) 的資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 肝炎病毒迅速、POC檢驗概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期

第4章 在肝炎病毒迅速、POC檢驗:各企業現在臨床實驗中的開發中產品

  • 肝炎病毒迅速、POC檢驗的企業:各臨床實驗階段的開發中產品
  • 肝炎病毒迅速、POC檢驗:各臨床實驗階段的開發中產品

第5章 肝炎病毒迅速、POC檢驗的企業、產品概要

  • Akers Biosciences Inc
    • 開發中產品及進行中的臨床實驗概要
  • Alere Inc
  • Atomo Diagnostics Pty Limited
  • Biocartis SA
  • bioLytical Laboratories Inc
  • Biosurfit, SA
  • Biotech Consortium India Ltd
  • Cepheid
  • Chembio Diagnostic Systems Inc
  • ChipCare Corp
  • Co-Diagnostics HBDC, Inc.
  • Correlia Biosystems, Inc.
  • Daktari Diagnostics, Inc.
  • Diagnostics For All
  • Fast-track diagnostics S.a.r.l.
  • GeneBio Systems Inc
  • genedrive plc
  • Group K Diagnostics
  • ImmunoScience Inc
  • MedMira Inc.
  • Micronics Inc
  • Molbio Diagnostics Pvt. Ltd.
  • NOWDiagnostics
  • OPKO Health Inc
  • Sedia Biosciences Corp
  • University of California Irvine
  • Wave 80 Biosciences Inc
  • Xagenic Inc.

第6章 肝炎病毒迅速、POC檢驗市場:目前的趨勢

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0820EPD

GlobalData's Medical Devices sector report, "Hepatitis Viruses Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019" provides an overview of Hepatitis Viruses Rapid Tests & Point of Care (POC) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hepatitis Viruses Rapid Tests & Point of Care (POC) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hepatitis Viruses Rapid Tests & Point of Care (POC) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hepatitis Viruses Rapid Tests & Point of Care (POC) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hepatitis Viruses Rapid Tests & Point of Care (POC) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 9

  • 2.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) Overview 9
  • Hepatitis Viruses Rapid Tests & Point of Care (POC) are the rapid diagnostic tests used to detect the hepatitis viruses or the virus antigens antibodies and generate results immediately in a limited resource setting. 9

3 Products under Development 10

  • 3.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 10
  • 3.2 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 11
  • 3.3 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 12
  • 3.4 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 13
  • 3.5 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials 14

4 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products under Development by Companies 15

  • 4.1 Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 15
  • 4.2 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 17

5 Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies and Product Overview 19

  • 5.1 Abbott Diagnostics Company Overview 19
    • 5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.2 Access Bio Inc Company Overview 20
    • 5.2.1 Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.3 Akers Biosciences Inc Company Overview 21
    • 5.3.1 Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.4 Alere Inc Company Overview 22
    • 5.4.1 Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.5 Atomo Diagnostics Pty Ltd Company Overview 23
    • 5.5.1 Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.6 Biocartis Group NV Company Overview 24
    • 5.6.1 Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.7 bioLytical Laboratories Inc Company Overview 26
    • 5.7.1 bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.8 Biosurfit, SA Company Overview 27
    • 5.8.1 Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview 27
  • 5.9 Biotech Consortium India Ltd Company Overview 28
    • 5.9.1 Biotech Consortium India Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.10 Biotech Resources Pty Ltd Company Overview 29
    • 5.10.1 Biotech Resources Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.11 Blink AG Company Overview 30
    • 5.11.1 Blink AG Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.12 Cepheid Company Overview 31
    • 5.12.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.13 Chembio Diagnostic Systems Inc Company Overview 32
    • 5.13.1 Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.14 ChipCare Corp Company Overview 34
    • 5.14.1 ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.15 Co-Diagnostics HBDC, Inc. Company Overview 35
    • 5.15.1 Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.16 Co-Diagnostics Inc Company Overview 36
    • 5.16.1 Co-Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 36
  • 5.17 Correlia Biosystems, Inc. Company Overview 37
    • 5.17.1 Correlia Biosystems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.18 CrossLife Technologies Inc Company Overview 38
    • 5.18.1 CrossLife Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.19 Daktari Diagnostics, Inc. Company Overview 39
    • 5.19.1 Daktari Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 39
  • 5.20 DCN Diagnostics Company Overview 40
    • 5.20.1 DCN Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.21 Diagnostics For All Inc Company Overview 41
    • 5.21.1 Diagnostics For All Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.22 Diagnostics for the Real World Limited Company Overview 43
    • 5.22.1 Diagnostics for the Real World Limited Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.23 DxDiscovery, Inc. Company Overview 45
    • 5.23.1 DxDiscovery, Inc. Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.24 Fast Track Diagnostics Ltd. Company Overview 46
    • 5.24.1 Fast Track Diagnostics Ltd. Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.25 genedrive plc Company Overview 47
    • 5.25.1 genedrive plc Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.26 Group K Diagnostics Company Overview 50
    • 5.26.1 Group K Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.27 HLL Lifecare Ltd Company Overview 52
    • 5.27.1 HLL Lifecare Ltd Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.28 ImmunoScience Inc Company Overview 53
    • 5.28.1 ImmunoScience Inc Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.29 MedMira Inc Company Overview 55
    • 5.29.1 MedMira Inc Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.30 Micronics Inc Company Overview 56
    • 5.30.1 Micronics Inc Pipeline Products & Ongoing Clinical Trials Overview 56
  • 5.31 Mologic Ltd Company Overview 58
    • 5.31.1 Mologic Ltd Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.32 NanoComposix Inc Company Overview 59
    • 5.32.1 NanoComposix Inc Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.33 NanoRepro AG Company Overview 60
    • 5.33.1 NanoRepro AG Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.34 NOWDiagnostics Inc Company Overview 61
    • 5.34.1 NOWDiagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.35 Quidel Corp Company Overview 63
    • 5.35.1 Quidel Corp Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.36 Sedia Biosciences Corp Company Overview 64
    • 5.36.1 Sedia Biosciences Corp Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.37 SLS Cell Cure Technologies Pty Ltd Company Overview 67
    • 5.37.1 SLS Cell Cure Technologies Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.38 University of California Irvine Company Overview 69
    • 5.38.1 University of California Irvine Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.39 Wave 80 Biosciences Inc Company Overview 70
    • 5.39.1 Wave 80 Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.40 Xagenic Inc Company Overview 73
    • 5.40.1 Xagenic Inc Pipeline Products & Ongoing Clinical Trials Overview 73

6 Hepatitis Viruses Rapid Tests & Point of Care (POC) - Recent Developments 74

  • 6.1 Nov 04, 2019: Quotient reports second quarter fiscal 2020 financial results 74
  • 6.2 Oct 29, 2019: Merck announces third-quarter 2019 financial results 76
  • 6.3 Oct 03, 2019: genedrive: Audited final results 80
  • 6.4 Sep 05, 2019: Biocartis announces H1 2019 results 85
  • 6.5 Aug 07, 2019: Merck announces leadership changes to investor relations team 91
  • 6.6 Aug 05, 2019: Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2020 Results 91
  • 6.7 Jul 30, 2019: Merck announces second-quarter 2019 financial results 93
  • 6.8 Jul 02, 2019: Quotient Board announces contract extension of CEO Franz Walt 97
  • 6.9 Jun 20, 2019: Merck hosts 2019 investor day outlining business momentum, strong expected growth and focus on innovative research and development 98
  • 6.10 Jun 14, 2019: Drug Makers Sue to Block requirement for Listing Prices in TV Ads 98

7 Appendix 127

  • 7.1 Methodology 127
  • 7.2 About GlobalData 130
  • 7.3 Contact Us 130
  • 7.4 Disclaimer 130

List of Tables

  • Table 1: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 11
  • Table 2: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 12
  • Table 3: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 14
  • Table 4: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 15
  • Table 5: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials 16
  • Table 6: Hepatitis Viruses Rapid Tests & Point of Care (POC) Companies - Pipeline Products by Stage of Development 17
  • Table 7: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 19
  • Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 21
  • Table 9: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Status 21
  • Table 10: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Description 21
  • Table 11: Access Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 22
  • Table 12: RDT - HCV Infection - Product Status 22
  • Table 13: RDT - HCV Infection - Product Description 22
  • Table 14: Akers Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 15: PIFA Hep B / Hep C - Product Status 23
  • Table 16: PIFA Hep B / Hep C - Product Description 23
  • Table 17: Alere Inc Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 18: Alere q Analyzer - HCV VL Assay - Product Status 25
  • Table 19: Alere q Analyzer - HCV VL Assay - Product Description 25
  • Table 20: Atomo Diagnostics Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 21: AtomoRapid - Hepatitis C - Product Status 26
  • Table 22: AtomoRapid - Hepatitis C - Product Description 26
  • Table 23: Biocartis Group NV Pipeline Products & Ongoing Clinical Trials Overview 27
  • Table 24: Idylla Viral Load Assay - HBV - Product Status 27
  • Table 25: Idylla Viral Load Assay - HBV - Product Description 27
  • Table 26: Idylla Viral Load Assay - HCV - Product Status 29
  • Table 27: Idylla Viral Load Assay - HCV - Product Description 29
  • Table 28: bioLytical Laboratories Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 29: INSTI Test - Hepatitis C - Product Status 30
  • Table 30: INSTI Test - Hepatitis C - Product Description 30
  • Table 31: Biosurfit, SA Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 32: Spinit Device - Hepatitis C Biomarker Assay - Product Status 31
  • Table 33: Spinit Device - Hepatitis C Biomarker Assay - Product Description 31
  • Table 34: Biotech Consortium India Ltd Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 35: Diagnostic Kit - Hepatitis A - Product Status 32
  • Table 36: Diagnostic Kit - Hepatitis A - Product Description 32
  • Table 37: Biotech Resources Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 38: ATR-FTIR System - Hepatitis B & C - Product Status 34
  • Table 39: ATR-FTIR System - Hepatitis B & C - Product Description 34
  • Table 40: Blink AG Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 41: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Status 35
  • Table 42: Point-Of-Care Test - Hepatitis C Virus RNA Detection - Product Description 35
  • Table 43: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 36
  • Table 44: GeneXpert Omni - HCV Viral Load - Product Status 36
  • Table 45: GeneXpert Omni - HCV Viral Load - Product Description 36
  • Table 46: Chembio Diagnostic Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 47: DPP Hepatitis C Virus Assay - Product Status 37
  • Table 48: DPP Hepatitis C Virus Assay - Product Description 37
  • Table 49: Next Generation DPP HCV Assay - Product Status 38
  • Table 50: Next Generation DPP HCV Assay - Product Description 38
  • Table 51: Rapid Diagnostic Test - HCV - Product Status 38
  • Table 52: Rapid Diagnostic Test - HCV - Product Description 38
  • Table 53: ChipCare Corp Pipeline Products & Ongoing Clinical Trials Overview 39
  • Table 54: Diagnostic Assay - Hepatitis C - Product Status 39
  • Table 55: Diagnostic Assay - Hepatitis C - Product Description 39
  • Table 56: Co-Diagnostics HBDC, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 57: Molecular Diagnostic Kit - Hepatitis B - Product Status 40
  • Table 58: Molecular Diagnostic Kit - Hepatitis B - Product Description 40
  • Table 59: Co-Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 60: Diagnostic Test - Hepatitis C - Product Status 41

List of Figures

  • Figure 1: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Stage of Development 10
  • Figure 2: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Territory 11
  • Figure 3: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Regulatory Path 12
  • Figure 4: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Pipeline Products by Estimated Approval Date 13
  • Figure 5: Hepatitis Viruses Rapid Tests & Point of Care (POC) - Ongoing Clinical Trials 14
Back to Top